Summit Therapeutics Inc.

NasdaqGM:SMMT

Sector

🏥 Health Care

Industries

🧬 Biotechnology

🔬 Clinical Trials

💊 Pharmaceuticals

Location

United States

Market Cap

USD 20.98 B

Share Price

USD 28.25

Avg Daily Volume

3,803,030

Change (1 day)

-1.43%

Change (1 year)

162.06%

Change (YTD)

58.26%

Summit Therapeutics Inc. EBIT Margin for the Trailing 12 Months (TTM) ending September 30, 2023: -246,546.32%

Summit Therapeutics Inc. EBIT Margin is -246,546.32% for the Trailing 12 Months (TTM) ending September 30, 2023, a 2,633.11% change year over year. EBIT ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses.

Summit Therapeutics Inc. EBIT Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was -9,020.71%, a 110.79% change year over year.
Summit Therapeutics Inc. EBIT Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was -4,279.52%.
Summit Therapeutics Inc. EBIT Margin for the Trailing 12 Months (TTM) ending October 31, 2019 was -2,459.22%, a -52,620.43% change year over year.